Lung cancer
Conditions
Interventions
Case series:Using new technology
Sponsors
The Comprehensive Cancer Center, Affiliated Drum-Tower Hospital,Medical School of Nanjing University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Imaging confirmed a lung occupying position, suspected of malignancy, and it is expected that histopathology can be obtained by CT-guided percutaneous lung biopsy. Including the following situations: 1) Newly discovered or isolated solitary nodules or masses that are enlarged during follow-up; 2) multiple pulmonary nodules with no history of malignant disease, or nodules that are known to have a history of malignant disease but are not dissipated after treatment; 3). Lung invasive lesions that persist and are poorly absorbed after treatment; 2. ECOG score = 3 points; 3. Patients need to meet the following hematological indicators: 1) Neutrophil count = 1.5 × 10^9/L; 2) Platelet count = 50 × 10^9/L; 3) There is no obvious abnormality in coagulation function (INR<1.5); 4. The relevant information and course record of the patient during the hospitalization process are detailed and complete, including details of the operation process; Fine records, processing and results of the obtained specimens, complications, treatment and outcomes. 5. Informed consent has been signed; 6. Be able to follow the research protocol.
Exclusion criteria
Exclusion criteria: 1. Those with abnormal coagulation function; 2. Severe dyscrasia, cardiopulmonary dysfunction can not tolerate this test; 3. Severe emphysema, pneumothorax, set of puncture needles on the lungs, pulmonary cysts, etc. may increase the risk of pneumothorax, or patients may not be able to tolerate pneumothorax after puncture; 4. Pulmonary heart disease, pulmonary hypertension, pulmonary vascular disease, severe hypertension, uncontrolled, may increase the risk of bleeding or worsen the condition; 5. Severe cough can not cooperate; 6. Acute myocardial infarction within 6 weeks, chronic liver and kidney dysfunction, etc. should not be lung puncture; 7. Certain drugs, such as the anticoagulant drugs aspirin and clopidogrel, may increase the risk of bleeding, because the inhibition of platelet after oral dose of aspirin lasts for 4-7 days, and platelet life is 7-10 days, it is recommended before puncture. After one week of discontinuation, it is recommended that warfarin be discontinued until the coagulation index is normal before puncture; 8. The patient has uncontrollable coronary artery disease or asthma, uncontrollable cerebrovascular disease or other diseases that the investigator believes are unincorporated; 9. Clinical or psychological or social factors influence informed consent or research implementation; 10. Any uncertainty that affects patient safety or compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| body temperature;blood pressure;Breathe;oxygen saturation;Hemoptysis; | — |
Countries
China
Contacts
Public ContactRu-Tian Li
The Comprehensive Cancer Center, Affiliated Drum-Tower Hospital,Medical School of Nanjing University
Outcome results
None listed